9th Annual Biomarkers Congress

Oncology: Genentech

Total Score People Score Events Score
26 22 21
Date Event Presentation Speakers
February 10, 2014 Predictive Preclinical Models in Oncology Modeling Efficacy and Resistance of Hedgehog Pathway Inhibitors in Cancer Frederic J. de Sauvage
October 28, 2013 Tumor Immunology and Immunotherapy Oncology meets immunology: targeting PD-L1 in combination Ira Mellman
May 31, 2013 ASCO Annual Meeting 2013 The Many Faces of Hepatocellular Carcinoma: From Biology to Treatment Robert Kelley
April 6, 2013 AACR Annual Meetings Expanding the Druggable Genome Chairperson: Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN Domagoj Vucic
Mitotic Checkpoints Driving Cancer Therapeutic Strategies Chairperson: Peter K. Jackson, Genentech, Inc., South San Francisco, CA Peter K Jackson
February 12, 2011 Cancer Control by Tumor Suppressors and Immune Effectors (J8) Dendritic Cells (J7) | MHC Class II Pathways Ira Mellman
February 8, 2011 Clinical Trial Forecasting, Budgeting, and Project Management TOPIC: Vendor Management at the Project Level: Strategies for Establishing and Maintaining Relationships Internally and Externally for Successful Clinical Trial Execution Rhonda Benotti
January 12, 2011 Antibodies for the 21st Century Endogenous Anti-IFNa Autoantibodies in Patients with Systemic Lupus Erythematosus are Associated with Decreased IFN-Pathway and Disease Activity Alyssa Morimoto
May 20, 2010 Bioanalytical Challenges for Optimizing Protein Therapeutics Free vs. Total Ligand Binding Assays: Points to Consider in Drug Development Jihong Yang
Immunogenicity: Regulatory and Technical Overview with Case Studies of Assay Challenges Eric Wakshull
May 19, 2010 Towards Personalized Cancer Medicine Role of the Microenvironment in VEGF-Independent Angiogenesis Napoleone Ferrara
August 5, 2009 New Frontiers in Cancer Drug Development Cancer Stem Cells Chia Portera
Targeting the Hedgehog Pathway in Cancer Treatment Chia Portera
Bevacizumab in Patients with Previously Treated Glioblastoma Asha Das
January 26, 2009 Preclinical Biomarker Discovery and Validation for a Small Molecule Inhibitor of MEK Kinase Mark R Lackner
January 26, 2009 Biomarker Assay Development Preclinical Biomarker Discovery and Validation for a Small Molecule Inhibitor of MEK Kinase Mark R Lackner
January 26, 2009 Translational Cancer Medicine Preclinical Biomarker Discovery and Validation for a Small Molecule Inhibitor of MEK Kinase Mark R Lackner
January 26, 2009 7th Annual Partnering with Central Labs B1 : How to Reduce the Burden on Smaller Sponsor Clinical Team-The Cross Functional Approach Rhonda Benotti
Track A : Best Practices for Collecting and Integrating Data in International Clinical Trials Elena Gogoleva
January 5, 2009 High Content Analysis Chemical Reporters for Probing and Visualizing Lipoproteins and Lipids in Cells Rami Hannoush
Utility of Time-Resolved Binding Date for Fragment-Based Screening and HTS Hit Validation Using SPR Biosensors Anthony M Giannetti
Profiling p53 Networks by Cell-Based Multiplex Imaging Rami Hannoush
November 17, 2008 BIO-Europe 2008 Maximizing Your Deal: The Business Case for Translational Medicine in Oncology Aron Knickerbocker
October 31, 2008 Changing Paradigms in Lung Cancer Care and Advances in the Pipeline Therapeutic Workshop Philippe Bishop
June 18, 2008 Accelerating Anticancer Agent Development and Validation Workshop Panel Discussion David P Schenkein
Proof of Concept to the Drug Developer David P Schenkein
Panel Discussion David P Schenkein
May 30, 2008 ASCO Annual'08 Meeting professional development-- Contract Negotiations for Your First Job in Industry, Private Practice, or Academia Sean P. Bohen
April 28, 2008 Clinical Development of Therapeutic Antibodies The Development of Antiangiogenics in Lung Cancer Jane Huang
April 27, 2008 Phage Display of Antibodies and Peptides Synthetic Antibodies Germaine Fuh
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.